<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Issues related to gastrointestinal disease in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Issues related to gastrointestinal disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Issues related to gastrointestinal disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2705817494"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>At the end of 2019, SARS-CoV-2, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. Coronavirus disease 2019 (COVID-19) primarily manifests as a lung infection with symptoms ranging from those of a mild upper respiratory infection to severe pneumonia, acute respiratory distress syndrome, and death. COVID-19 disproportionately affects patients with pre-existing comorbidities and/or older adults.</p><p>This topic will discuss COVID-19-related issues for patients with gastrointestinal (GI) disease. As understanding of COVID-19 continues to evolve, the approach to diagnosis and management may require modification as well. </p><p>Other important aspects of COVID-19 infection are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128410.html" rel="external">"COVID-19: Issues related to liver disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2490743491"><span class="h1">POSSIBLE RISK FACTORS FOR COVID-19</span><span class="headingEndMark"> — </span>Some patients with chronic gastrointestinal (GI) disease may be at increased risk for more severe illness due to COVID-19. Potential risk factors in these patients include their chronic inflammatory disease, comorbidities (eg, diabetes mellitus), and the use of glucocorticoids [<a href="#rid1">1</a>]. </p><p>It is unclear if the use of proton pump inhibitors (PPIs) is associated with an increased risk of COVID-19. In a cross-sectional survey of 86,602 individuals, 53,130 reported prior abdominal pain, acid reflux, heartburn, and regurgitation and provided data on H2 receptor antagonist (H2RA) and PPI use [<a href="#rid2">2</a>]. Of these, 3386 individuals (6.4 percent) self-reported a positive COVID-19 test result. In analyses adjusted for socioeconomic, lifestyle, and clinical comorbidities, patients who reported PPI use were more likely to report a positive COVID-19 test result with a dose-dependent increase in the odds of a positive test result (PPI once daily odds ratio [OR] 2.15, 95% CI 1.9-2.4; PPI twice daily OR 3.7, 95% CI 2.9-4.6). H2RA use was not associated with an increase in risk. It is possible that this association is due to residual confounding; further studies are required to validate these results. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'COVID-19'</a>.)</p><p>For patients with inflammatory bowel disease (IBD), studies have suggested that the prevalence of COVID-19 is not higher than that of the general population [<a href="#rid3">3-6</a>]. However, the use of glucocorticoids, but not anti-TNF therapy, may increase the risk of severe COVID-19 in patients with IBD [<a href="#rid5">5,7,8</a>]. (See <a class="local">'Patients with COVID-19'</a> below.)</p><p>The GI tract may be susceptible to SARS-CoV-2 infection because of widely expressed angiotensin-converting enzyme 2 (ACE2) receptors in the intestine [<a href="#rid9">9</a>]. ACE2 is a receptor for SARS-CoV-2 virus, and digestive symptoms associated with SARS-CoV-2 infection may be caused by direct viral attack as well as tissue and organ damage due to the immune response [<a href="#rid10">10,11</a>]. Staining of tissue specimens from patients with COVID-19 demonstrated that the positive areas were mainly distributed in the cytoplasm of gastric and intestinal epithelial cells and the cilia of glandular epithelial cells [<a href="#rid10">10</a>]. In addition, viral nucleocapsid protein was detected in the cytoplasm of gastric, duodenal, and rectal glandular epithelial cells. However, understanding of the pathogenesis of digestive disease associated with SARS-CoV-2 virus is evolving, and its effects on existing chronic GI disorders remains uncertain [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H538481135"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H1965236210"><span class="h2">Symptoms of disease flare that can mimic COVID-19</span><span class="headingEndMark"> — </span>The clinical presentation of several gastrointestinal (GI) diseases (eg, Crohn disease, ulcerative colitis) can mimic COVID-19 infection [<a href="#rid13">13</a>]. Examples include diseases that manifest with diarrhea, nausea, vomiting and/or anorexia [<a href="#rid14">14,15</a>]. Thus, for patients with an existing diagnosis of chronic GI disease, the clinician will need to assess whether symptoms are related to a disease flare or COVID-19. The approach to testing for COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H592287982"><span class="h3">Digestive symptoms</span><span class="headingEndMark"> — </span>Patients with COVID-19 typically present with fever and respiratory symptoms; however, GI symptoms have been commonly reported in patients diagnosed with COVID-19 [<a href="#rid9">9,14,16-19</a>]. For example, in a study including 318 adult patients who were hospitalized with COVID-19, 195 patients (61 percent) reported at least one digestive symptom, and the most frequently reported symptoms were anorexia in 110 patients (35 percent), diarrhea in 107 patients (34 percent), and nausea in 84 patients (26 percent) [<a href="#rid16">16</a>]. Similarly, in another study of 204 patients with COVID-19, 103 patients (51 percent) reported at least one digestive symptom, and the most commonly reported symptoms were anorexia and diarrhea [<a href="#rid14">14</a>]. </p><p>Some patients with COVID-19 have presented with isolated GI symptoms that may precede the development of respiratory symptoms [<a href="#rid20">20,21</a>]. As an example, in a study of 1141 patients with COVID-19, 183 patients (16 percent) presented with GI symptoms (eg, diarrhea, nausea, vomiting) in the absence of respiratory complaints [<a href="#rid20">20</a>]. </p><p>Limited data have suggested that diarrheal symptoms in patients with COVID-19 have been associated with a more favorable prognosis and with detection of virus RNA in stool [<a href="#rid17">17,22-24</a>]. In a cohort study including 190 hospitalized patients with COVID-19, diarrheal symptoms were associated with lower risk of in-hospital mortality compared with the absence of diarrhea (OR 0.38, 95% CI 0.17-0.86) [<a href="#rid24">24</a>]. One possible explanation is that the SARS-CoV-2 virus preferentially targets the intestinal mucosa in some patients who present with GI symptoms, and such patients experience a milder disease course than patients with respiratory symptoms. In a study of 84 patients with SARS-CoV-2 pneumonia, stool samples from patients with diarrhea had higher rates for detecting SARS-CoV-2 virus RNA by real time polymerase chain reaction compared with patients without diarrhea (69 versus 17 percent) [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H1309678104"><span class="h3">Hepatic manifestations</span><span class="headingEndMark"> — </span>The clinical presentation of COVID-19 may include hepatic manifestations such as acute hepatitis and abnormal liver biochemical tests [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/128410.html" rel="external">"COVID-19: Issues related to liver disease in adults"</a>.) </p><p class="headingAnchor" id="H3289220573"><span class="h2">When to test for COVID-19 in patients with GI symptoms</span><span class="headingEndMark"> — </span>The diagnosis of COVID-19 is suspected primarily in patients with the new onset of fever and/or respiratory tract symptoms (eg, cough, dyspnea), while other consistent symptoms include myalgias, diarrhea, and smell or taste abnormalities. </p><p>For patients with GI symptoms, we favor testing for COVID-19 in the following cases [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized patients with the new onset of GI symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Outpatients with the new onset of GI symptoms for over 48 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with established GI disease (eg, Crohn disease) with symptoms suggestive of a disease flare (eg, diarrhea, vomiting) </p><p></p><p>In a minority of patients, GI symptoms such as diarrhea may be the presenting symptom or may precede the development of respiratory symptoms [<a href="#rid20">20,21,26</a>]. While the diagnosis of COVID-19 may be suspected based on presenting symptoms, additional factors that inform the decision to perform testing include the patient's geographic location, risk of exposure, rate of community transmission, and the availability of testing. The epidemiology and diagnosis of COVID-19 are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>.)</p><p>Additionally, stool testing to exclude <em>Clostridioides</em> (formerly<em> Clostridium</em>)<em> difficile </em>infection is obtained for patients with diarrhea who are at risk for <em>C</em>.<em> difficile </em>infection (eg, recent antibiotic use) or who may require therapy (eg, antidiarrheal agents) to control symptoms. (See <a class="local">'Managing symptoms related to viral infection'</a> below.)</p><p class="headingAnchor" id="H1720317243"><span class="h2">Gastrointestinal complications</span><span class="headingEndMark"> — </span>Several gastrointestinal complications have been reported in critically ill patients with COVID-19 [<a href="#rid27">27,28</a>]. In an observational study including 184 patients with acute respiratory distress syndrome (ARDS), patients with COVID-19 related ARDS had higher rates of gastrointestinal complications compared with non-COVID-19 matched ARDS (74 versus 37 percent; incidence rate ratio 2.33, 95% CI 1.52-3.63) [<a href="#rid27">27</a>]. Specifically, COVID-19 was associated with higher rates of ileus (48 versus 22 percent), bowel ischemia (4 versus 0 percent), and elevated aminotransferase levels (55 versus 27 percent). While patients in this single center study were propensity matched by age, comorbidity, and Sequential Organ Failure Assessment score on intensive care unit (ICU) admission, they were not matched by inflammatory markers which are known to be associated with worse COVID-19 outcomes. It is also unclear if ileus and bowel ischemia are associated with higher opioid requirements and COVID-19-related coagulopathy. Further studies are needed to validate these findings. (See  <a class="medical medical_review" href="/d/html/129171.html" rel="external">"COVID-19: Gastrointestinal symptoms and complications"</a>.)</p><p class="headingAnchor" id="H4245199647"><span class="h1">MANAGEMENT PRINCIPLES</span></p><p class="headingAnchor" id="H3064281088"><span class="h2">General strategies to reduce risk of infection</span><span class="headingEndMark"> — </span>In locations where community transmission of COVID-19 is widespread, preventive measures to reduce exposure to the virus include (see  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>General preventive measures such as hand washing and respiratory hygiene (eg, covering the cough or sneeze).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with stable disease and without known or suspected COVID-19, continuing the established medication regimen to avoid a disease flare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on glucocorticoids for treating inflammatory bowel disease, therapy should not be abruptly discontinued, but should be used at the lowest dose possible to control the underlying disease, regardless of COVID-19 exposure or infection status.</p><p></p><p>Preventive strategies including vaccination are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H1648704910"><span class="h2">Managing symptoms related to viral infection</span><span class="headingEndMark"> — </span>For symptomatic therapy for infectious diarrhea, the antidiarrheal agent <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> can be used in an initial dose of 4 mg and with a maximum daily dose of 16 mg in patients without fever, bloody stools, or risk factors for <em>Clostridioides</em> (<em>C</em>., formerly<em> Clostridium</em>)<em> difficile </em>infection. Use of loperamide for patients with acute diarrhea is discussed separately. (See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Management'</a>.)</p><p>For patients with symptoms of gastroenteritis (eg, nausea, vomiting), antiemetic drugs can often help relieve symptoms, in addition to supportive measures including oral or intravenous hydration. Management of patients with gastroenteritis and use of antiemetics are discussed separately. (See  <a class="medical medical_review" href="/d/html/16294.html" rel="external">"Acute viral gastroenteritis in adults", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.) </p><p>Symptomatic therapy for digestive symptoms may reduce the risk of complications such as electrolyte disturbances (eg, hypokalemia) or colonic ischemia related to volume depletion. (See  <a class="medical medical_review" href="/d/html/2564.html" rel="external">"Colonic ischemia"</a>.)</p><p>Specific management for COVID-19 is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="headingAnchor" id="H186566134"><span class="h2">Inflammatory bowel disease</span></p><p class="headingAnchor" id="H1287386011"><span class="h3">Diagnostic considerations</span><span class="headingEndMark"> — </span>For patients with symptoms of active inflammatory bowel disease (IBD; eg, diarrhea) who are also at risk for COVID-19 (eg, recent exposure), evaluation includes COVID-19 testing, stool studies to exclude enteric infections (eg, <em>C. difficile</em> infection), noninvasive inflammatory markers (eg, C-reactive protein, fecal calprotectin), and serum drug trough levels (for patients on biologic therapy). (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"</a>.)</p><p>However, in patients with COVID-19, nonspecific markers of inflammation (eg, C-reactive protein) may be elevated due to COVID-19 rather than IBD. (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.) </p><p>If fecal markers (eg, fecal calprotectin, lactoferrin) are not elevated, endoscopic evaluation is not necessary, as negative test results indicate the absence of active bowel inflammation. For most patients with an established diagnosis of IBD, elevated fecal inflammatory marker levels along with typical symptoms of active disease (eg, diarrhea) in the absence of infection are sufficient to initiate IBD treatment. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Pretreatment evaluation'</a>.)</p><p>Urgent endoscopic evaluation is reserved for patients in whom the results will change management [<a href="#rid6">6</a>]. For example, patients with suspected severe acute ulcerative colitis are typically started on glucocorticoids intravenously but still require at least a limited lower endoscopy with biopsies to confirm the diagnosis and exclude other conditions (eg, viral infection). (See  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis", section on 'Pretreatment evaluation'</a>.) </p><p class="headingAnchor" id="H3424360068"><span class="h3">Patients without COVID-19</span></p><p class="headingAnchor" id="H1758406630"><span class="h4">Patients with IBD in remission</span><span class="headingEndMark"> — </span>Available data have suggested that patients with IBD in remission are not at higher risk for COVID-19 and that such patients should continue maintenance therapy to sustain remission [<a href="#rid3">3,4,6</a>]. Discontinuing maintenance therapy has been associated with disease relapse that may require hospitalization and/or glucocorticoid therapy and may increase the risk for severe COVID-19 [<a href="#rid3">3,29</a>].</p><p>Therapies for maintaining remission in patients with Crohn disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Maintenance of remission'</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Maintenance therapy'</a>.)</p><p>Therapies for maintaining remission in patients with ulcerative colitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Maintenance of remission'</a> and  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Maintenance of remission'</a>.)</p><p class="headingAnchor" id="H4120618025"><span class="h4">Patients with active IBD</span><span class="headingEndMark"> — </span>For patients with a flare of Crohn disease or ulcerative colitis in the absence of COVID-19, adding or escalating anti-inflammatory or biologic therapy may be required for symptomatic improvement and inducing remission (see <a class="local">'Diagnostic considerations'</a> above). For example, therapeutic options for mild IBD include oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, aminosalicylates, and topical (rectal) therapy, while options for moderate to severe IBD include biologic therapies (eg, anti-tumor necrosis factor [TNF] agents, anti-integrin agents, anti-interleukin agents, or small molecules) [<a href="#rid6">6</a>].  </p><p>However, if systemic glucocorticoids are deemed necessary for patients with active IBD, the lowest dose of glucocorticoid that will result in clinical response is used for a short duration before transitioning to another therapy that is glucocorticoid-sparing [<a href="#rid6">6</a>]. For example, management of a patient who is hospitalized with severe ulcerative colitis in the absence of COVID-19 may include treatment with a glucocorticoid (eg, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 16 to 20 mg intravenously every eight hours) for three days, and if there is no clinical response, medical therapy is escalated to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid6">6,30,31</a>]. Surgery is an alternative option for patients who do not improve with medical therapy. Management of hospitalized patients with ulcerative colitis including escalating medical therapy is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p>Diagnosis, pretreatment assessment, and medical management of Crohn disease are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p></p><p>Diagnosis, pretreatment assessment, and medical management of ulcerative colitis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p></p><p class="headingAnchor" id="H2955044820"><span class="h3">Patients with COVID-19</span></p><p class="headingAnchor" id="H3971764635"><span class="h4">Adjusting IBD medications</span><span class="headingEndMark"> — </span>Adjustments to medication regimens in patients with IBD with suspected or known COVID-19 should be individualized based on the severity of infection, patient comorbidities, and the existing medication regimen, while balancing the risk of disease flare [<a href="#rid32">32</a>]. The goal of medication adjustment is to reduce immunosuppression during active viral infection to lower the risk of COVID-19-related complications (eg, pneumonia) [<a href="#rid33">33</a>]. Our overall approach for patients with IBD in remission includes [<a href="#rid34">34-36</a>] (see  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Therapies that can be continued without interruption:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a></p><p class="bulletIndent2"><span class="glyph">•</span>Aminosalicylates, including <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Topical rectal therapy (eg, topical glucocorticoid)</p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapies that may require temporary adjustment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic glucocorticoids – The approach to adjusting glucocorticoids depends on the severity of COVID-19:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with nonsevere COVID-19 (eg, outpatient status) – Reduce dose of systemic glucocorticoid (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose to &lt;20 mg daily) or transition to oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent3">Although systemic glucocorticoids convey an increased risk of infection and are a potential risk factor for developing severe COVID-19  (<a class="graphic graphic_table graphicRef127477" href="/d/graphic/127477.html" rel="external">table 1</a>), abrupt discontinuation is not possible, and patients should receive the lowest required dose for the shortest period of time necessary to minimize adverse reactions [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who present with or progress to severe COVID-19 (ie, oxygen requirement) – Continue systemic glucocorticoids without tapering in the setting of COVID-19. The decision to continue systemic glucocorticoids has been informed by data suggesting that low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> has a role in the management of severe COVID-19. The use of glucocorticoids for treating severe COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunomodulators – Hold thiopurines (ie, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>) and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for patients with active symptoms of COVID-19 until symptoms resolve.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> – Consider holding or reducing dose of tofacitinib (eg, 5 mg twice daily) for patients with active symptoms of COVID-19 until symptoms resolve. Tofacitinib, a small molecule Janus kinase inhibitor, has been associated with an increased risk of other viral infections (ie, herpes zoster infection), and its mechanism of action is to suppress T-cell function. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biologic agents – Consider delaying biologic therapy (anti-TNF agents, <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a>, or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>) for patients with active symptoms of COVID-19 until symptoms resolve.</p><p></p><p>Studies have identified risk factors for severe illness from COVID-19 among patients with IBD. In a registry-based observational study of 525 patients with IBD and COVID-19, severe infection (defined as intensive care unit [ICU] admission, ventilator use, or death) was reported in 37 patients (7 percent) [<a href="#rid7">7</a>]. In adjusted analyses, risk factors for severe disease included increasing age (odds ratio [OR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (OR 2.9, 95% CI 1.1-7.8), systemic glucocorticoid use (OR 6.9, 95% 2.3-20.5), and <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>/<a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> use (OR 3.1, 95% 1.3-7.7). Anti-TNF therapy was not associated with severe disease. This study supports the approach of reducing the use of systemic glucocorticoids for patients with IBD and nonsevere COVID-19 [<a href="#rid37">37,38</a>]. </p><p>Observational data have suggested that thiopurines were associated with increased risk of severe COVID-19. In a cohort study including 1439 patients with IBD and COVID-19, 112 patients (8 percent) experienced severe COVID-19 [<a href="#rid39">39</a>]. In adjusted analyses, combination therapy (ie, anti-TNF agent plus thiopurine) and thiopurine monotherapy were associated with higher risk of severe COVID-19 compared with anti-TNF monotherapy (OR 4.01, 95% CI 1.65-9.78 and OR 4.08, 95% CI 1.73-9.61, respectively). Any <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>/<a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> use was also associated with increased risk of severe COVID-19 compared with no mesalamine/sulfasalazine (OR 1.70, 95% CI 1.26-2.29) or with anti-TNF monotherapy (OR 3.52, 95% CI 1.93-6.45). However, it was unclear whether this association was related to unmeasured confounding factors. The risk of severe COVID-19 in patients treated with anti-interleukin and anti-integrin therapies was not significantly different compared with anti-TNF monotherapy. This study supports the approach of holding thiopurines for patients with IBD and COVID-19, while further studies are needed to evaluate the safety of mesalamine/sulfasalazine in the setting of active infection. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H652955880"><span class="h4">Resumption of therapy</span><span class="headingEndMark"> — </span>The optimal time to resume immunosuppressive medications after COVID-19 is uncertain, while expert consensus has stated that medications (eg, biologic therapies) that were held during symptomatic infection can be resumed after resolution of symptoms [<a href="#rid40">40,41</a>]. </p><p class="headingAnchor" id="H1511408316"><span class="h4">Prognosis</span><span class="headingEndMark"> — </span>There are accumulating data pertaining to outcomes in patients with IBD and COVID-19 [<a href="#rid5">5,7,41-43</a>]. In a registry study including 88 fully vaccinated patients with IBD who had COVID-19, five patients (6 percent) were hospitalized, three patients (3 percent) had severe disease, and one patient (1 percent) died [<a href="#rid43">43</a>]. Patients who required hospitalization tended to be older (mean age, 59 versus 39 years), on immunosuppressive therapy, and with comorbid conditions. </p><p>Case series including patients with COVID-19 and chronic inflammatory diseases (rheumatoid arthritis, IBD) have also provided outcome data [<a href="#rid5">5,41</a>]. As an example, in a study of 86 patients with COVID-19 in the setting of immune-mediated inflammatory disease (including 37 patients with IBD), 14 patients (16 percent) required hospitalization, and the mortality rate was 7 percent [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H841659339"><span class="h3">COVID-19 vaccination</span><span class="headingEndMark"> — </span>COVID-19 vaccines are safe to administer to patients with IBD, including those on immune-modifying therapy  (<a class="graphic graphic_table graphicRef130711" href="/d/graphic/130711.html" rel="external">table 2</a>) [<a href="#rid44">44,45</a>]. Data on the immunogenicity of the vaccines in this patient population demonstrate high rates of initial antibody response [<a href="#rid46">46-53</a>]. In a meta-analysis of 31 studies including 9447 patients with IBD who completed the COVID-19 vaccination series, the pooled seroconversion rate was 96 percent (95% CI 94-97 percent) [<a href="#rid50">50</a>]. Seroconversion rates were not significantly different by drug therapy (ie, biologics, small molecules, immunomodulators, and/or glucocorticoids). In most studies that reported durability of serologic response, antibody titers began declining four weeks after vaccination, with a faster rate of decline with anti-TNF agent and/or immunomodulator use [<a href="#rid54">54-56</a>]. These data provide some reassurance for patients on immunosuppressive medications but also lend support for additional vaccine doses in such patients  (<a class="graphic graphic_figure graphicRef138339" href="/d/graphic/138339.html" rel="external">figure 1</a>).</p><p>Guidance regarding administration of COVID-19 vaccines in immunocompromised patients is provided separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a>.)</p><p>Data have also suggested that full vaccination is effective for reducing risk of COVID-19 in patients with IBD [<a href="#rid46">46,57</a>]. In a Veterans Health Administration study of nearly 15,000 patients with IBD, patients with full vaccination status (ie, &gt;7 days after second dose of mRNA vaccine) but not partial vaccination status had lower risk of SARS-CoV-2 infection compared with unvaccinated patients (0.11 versus 1.34 percent, adjusted hazard ratio [HR] 0.31, 95% CI 0.17-0.56) [<a href="#rid57">57</a>]. IBD medication exposures in this cohort included patients on <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a>, biologic agents, thiopurines, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, or glucocorticoids. COVID-19 vaccine effectiveness did not differ significantly by the medication being used to treat IBD. </p><p class="headingAnchor" id="H3876794486"><span class="h1">DISEASE REGISTRIES</span><span class="headingEndMark"> — </span>Studies using data from disease-specific patient registries have reported outcomes in patients with COVID-19 and chronic gastrointestinal (GI) conditions [<a href="#rid58">58-60</a>]. In addition, efforts to analyze the long-term outcomes in such patients are ongoing.</p><p class="headingAnchor" id="H373353400"><span class="h1">IMPLICATIONS FOR ENDOSCOPY</span><span class="headingEndMark"> — </span>During the COVID-19 pandemic, nonurgent endoscopic procedures were deferred with goals of reducing transmission of SARS-CoV-2 virus infection, conserving personal protective equipment, and reserving clinical resources for managing patients with COVID-19. The decision to perform endoscopic procedures and the necessary protocols have been informed by local and institutional rules in addition to guidance from professional societies [<a href="#rid61">61,62</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p>Indications for urgent or emergent procedures that should not be delayed can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.asge.org%2Fhome%2Fresources%2Fkey-resources%2Fcovid-19-asge-updates-for-members%2Fgastroenterology-professional-society-guidance-on-endoscopic-procedures-during-the-covid-19-pandemic&amp;token=PyCvzdjLVi2iZqI1NNyBLn2%2B9jz3juOM2Tcb3YEAmQodjxITJYEYw0yHeOosVfurKCvini80NWBbqLzFtlWoE9UacXBN1OWrPxZHFIVssxKadH3GHP4jOLmYDn7AL4LzZAMB2d%2FAmwet81AS751vEW%2BpjVirr3MRvZV0ysmz%2FFxND28B2c1HuVjD5%2FWZ4otC&amp;TOPIC_ID=127965" target="_blank">American Society for Gastrointestinal Endoscopy</a> website. </p><p>Performing elective endoscopy while managing risk of COVID-19 has been informed by several factors including local prevalence of COVID-19 and vaccination rates [<a href="#rid63">63-65</a>]. General strategies for reducing the risk of transmitting infection during gastrointestinal (GI) endoscopy that have been endorsed by professional societies, including the use of personal protective equipment, can be accessed <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgi.org%2Fmedia%2Fcovid-19-and-gi%2F&amp;token=Og4ss9xZ8giAwuAeSJ0YNe2pcredmOD90IeC%2FRoG1C5Q0F0ofdct5ZAFxaiZzkik&amp;TOPIC_ID=127965" target="_blank">here</a>. </p><p>Infection control strategies for use during aerosol-generating procedures (eg, upper GI endoscopy, endoscopic retrograde cholangiopancreatography [ERCP], endoscopic ultrasound) are discussed separately. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the health care setting'</a>.)</p><p>Issues related to managing patients with COVID-19 and acute GI illness include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with GI bleeding</strong> – Reports suggest that anticoagulant use is common among hospitalized patients with COVID-19 and GI bleeding [<a href="#rid66">66-68</a>]. In a study including 4871 hospitalized patients with COVID-19 who did not require intensive care unit (ICU) level of care, 23 patients (0.5 percent, median age 75 years) had upper GI bleeding [<a href="#rid67">67</a>]. Eighteen of the 23 patients with bleeding (78 percent) were on anticoagulant therapy or thromboprophylaxis. Eighteen patients underwent upper endoscopy, and peptic ulcer disease was the most common finding. </p><p></p><p class="bulletIndent1">Some patients with COVID-19 and nonvariceal upper GI bleeding have been successfully managed with medical therapy only (ie, continuous intravenous proton pump inhibitor and optimizing coagulation status) [<a href="#rid67">67,69</a>]. For example, in a series of six patients with acute upper GI bleeding and COVID-19 pneumonia, management included intravenous proton pump inhibitor and clinical observation, and no patients required urgent endoscopy during their hospitalization [<a href="#rid66">66</a>]. Rationale for this conservative approach also includes data that have suggested that delaying endoscopy for 24 hours was not associated with increased mortality in patients with acute upper GI bleeding [<a href="#rid70">70</a>]. </p><p></p><p class="bulletIndent1">For most patients with lower GI bleeding in the setting of COVID-19, endoscopic evaluation can be initially delayed and then performed on an outpatient basis after resolution of the acute illness [<a href="#rid69">69</a>]. Timing of endoscopy for patients with GI bleeding is discussed separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>.)</p><p></p><p class="bulletIndent1">Data have suggested that for patients who were hospitalized for GI bleeding during the COVID-19 pandemic, bleeding may have been more severe but was associated with fewer endoscopic procedures [<a href="#rid71">71</a>]. In a study of 211 hospitalized patients with GI bleeding, onset of bleeding during the COVID-19 outbreak was associated with lower rates of endoscopic evaluation compared with patients who presented prior to COVID-19 (28 versus 50 percent; adjusted odds ratio [OR] 0.32, 95% CI 0.15-0.72) [<a href="#rid71">71</a>]. However, patients who were treated for GI bleeding during the COVID-19 outbreak were more likely to require blood transfusion (adjusted OR 2.86, 95% CI 1.25-6.55) and to have a longer length of stay (adjusted OR 2.62, 95% 1.17-5.84). Additional studies are needed to examine the impact of COVID-19 on outcomes for patients with GI bleeding who presented during the pandemic. </p><p></p><p class="headingAnchor" id="H1069624616"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H3457342993"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>)</p><p></p><p class="headingAnchor" id="H3147537178"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Digestive symptoms </strong>– Patients with COVID-19 typically present with fever and respiratory symptoms; however, gastrointestinal (GI) symptoms (eg, anorexia, diarrhea, nausea) have been reported in patients diagnosed with COVID-19. (See <a class="local">'Digestive symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 testing </strong>– We favor testing for COVID-19 in the following patients, even in the absence of respiratory symptoms (see <a class="local">'When to test for COVID-19 in patients with GI symptoms'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalized patients with new onset of GI symptoms</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Outpatients with new onset of GI symptoms for over 48 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with established GI disease (eg, Crohn disease) with symptoms suggestive of a disease flare (eg, diarrhea, vomiting)</p><p></p><p class="bulletIndent1">While the diagnosis of COVID-19 may be suspected based on presenting symptoms, additional factors that inform the decision to perform testing include the patient's geographic location, risk of exposure, rate of community transmission, and the availability of testing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic considerations </strong>– For patients with symptoms of active inflammatory bowel disease ([IBD]; eg, diarrhea) who are also at risk for COVID-19, evaluation includes COVID-19 testing, stool studies to exclude enteric infections, noninvasive inflammatory markers (eg, fecal calprotectin), and serum drug trough levels (for patients on biologic therapy). (See <a class="local">'Diagnostic considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with IBD </strong>– Patients with IBD in remission should continue maintenance therapy to sustain remission. Discontinuing maintenance therapy is associated with disease relapse that may require hospitalization and/or glucocorticoid therapy and may increase the risk for severe COVID-19. (See <a class="local">'Patients with IBD in remission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive strategies </strong>– Strategies for reducing the risk of transmitting SARS-CoV-2 virus during GI endoscopy that have been endorsed by professional societies can be accessed <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgastro.org%2Fpractice-resources%2Fpractice-tools%2Fcovid-19%2F&amp;token=sX8xxkPP8kKyhj3sZbNUo7yi98BNDYHfhGSJa4D3HqS%2BYq7AYfJBiqKgHOnD4O0MYx2XKdk2Z1HL%2FjWUMhF4pA%3D%3D&amp;TOPIC_ID=127965" target="_blank">here</a>. (See <a class="local">'Implications for endoscopy'</a> above and <a class="local">'Society guideline links'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (Accessed on May 12, 2020).</li><li class="breakAll">Alamario CV, Chey WD, Spiegel BMR. 2020. AM J Gastro [in press]. https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf (Accessed on July 13, 2020).</li><li><a class="nounderline abstract_t">Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020; 5:425.</a></li><li><a class="nounderline abstract_t">Norsa L, Indriolo A, Sansotta N, et al. Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy. Gastroenterology 2020; 159:371.</a></li><li><a class="nounderline abstract_t">Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med 2020; 383:85.</a></li><li><a class="nounderline abstract_t">Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology 2020; 159:350.</a></li><li><a class="nounderline abstract_t">Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020; 159:481.</a></li><li><a class="nounderline abstract_t">Bangma A, Voskuil MD, Weersma RK. TNFα-Antagonist Use and Mucosal Inflammation Are Associated with Increased Intestinal Expression of SARS-CoV-2 Host Protease TMPRSS2 in Patients with Inflammatory Bowel Disease. Gastroenterology 2021; 160:2621.</a></li><li><a class="nounderline abstract_t">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.</a></li><li><a class="nounderline abstract_t">He J, Tao H, Yan Y, et al. Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2. Viruses 2020; 12.</a></li><li><a class="nounderline abstract_t">Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020; 94.</a></li><li><a class="nounderline abstract_t">Burgueño JF, Reich A, Hazime H, et al. Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Inflamm Bowel Dis 2020; 26:797.</a></li><li><a class="nounderline abstract_t">Occhipinti V, Pastorelli L. Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy. Inflamm Bowel Dis 2020; 26:793.</a></li><li><a class="nounderline abstract_t">Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020; 115:766.</a></li><li><a class="nounderline abstract_t">Tariq R, Saha S, Furqan F, et al. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clin Proc 2020; 95:1632.</a></li><li><a class="nounderline abstract_t">Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology 2020; 159:765.</a></li><li><a class="nounderline abstract_t">Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology 2020; 159:81.</a></li><li><a class="nounderline abstract_t">Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020; 69:997.</a></li><li><a class="nounderline abstract_t">Remes-Troche JM, Ramos-de-la-Medina A, Manríquez-Reyes M, et al. Initial Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 112 Patients From Veracruz in Southeastern Mexico. Gastroenterology 2020; 159:1179.</a></li><li><a class="nounderline abstract_t">Luo S, Zhang X, Xu H. Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). Clin Gastroenterol Hepatol 2020; 18:1636.</a></li><li><a class="nounderline abstract_t">Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; 69:1002.</a></li><li><a class="nounderline abstract_t">Wei XS, Wang X, Niu YR, et al. Diarrhea Is Associated With Prolonged Symptoms and Viral Carriage in Corona Virus Disease 2019. Clin Gastroenterol Hepatol 2020; 18:1753.</a></li><li><a class="nounderline abstract_t">Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020; 51:843.</a></li><li><a class="nounderline abstract_t">Schettino M, Pellegrini L, Picascia D, et al. Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study. Am J Gastroenterol 2021; 116:306.</a></li><li><a class="nounderline abstract_t">Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5:428.</a></li><li><a class="nounderline abstract_t">Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology 2020; 159:320.</a></li><li><a class="nounderline abstract_t">El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19. JAMA 2020; 324:1899.</a></li><li><a class="nounderline abstract_t">Kaafarani HMA, El Moheb M, Hwabejire JO, et al. Gastrointestinal Complications in Critically Ill Patients With COVID-19. Ann Surg 2020; 272:e61.</a></li><li><a class="nounderline abstract_t">An P, Ji M, Ren H, et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. Lancet Gastroenterol Hepatol 2020; 5:525.</a></li><li><a class="nounderline abstract_t">de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011; 92:2542.</a></li><li><a class="nounderline abstract_t">Occhipinti V, Saibeni S, Sampietro GM, Pastorelli L. Impact of COVID-19 Outbreak on the Management of Patients With Severe IBD: A Domino Effect. Gastroenterology 2021; 160:2196.</a></li><li><a class="nounderline abstract_t">D'Amico F, Peyrin-Biroulet L, Danese S. Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. Gastroenterology 2020; 158:2302.</a></li><li><a class="nounderline abstract_t">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.</a></li><li><a class="nounderline abstract_t">Rubin DT, Abreu MT, Rai V, et al. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology 2020; 159:6.</a></li><li class="breakAll">https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/ (Accessed on April 29, 2020).</li><li><a class="nounderline abstract_t">Kennedy NA, Jones GR, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020; 69:984.</a></li><li><a class="nounderline abstract_t">Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395:473.</a></li><li><a class="nounderline abstract_t">Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 2020; 395:1407.</a></li><li><a class="nounderline abstract_t">Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70:725.</a></li><li class="breakAll">https://gastro.org/news/how-to-treat-ibd-patients-during-the-pandemic/ (Accessed on June 19, 2020).</li><li><a class="nounderline abstract_t">Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, et al. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain). Gastroenterology 2020; 159:781.</a></li><li><a class="nounderline abstract_t">Aziz M, Fatima R, Haghbin H, et al. The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis. Inflamm Bowel Dis 2020; 26:e132.</a></li><li><a class="nounderline abstract_t">Spiera E, Ganjian DY, Zhang X, et al. Outcomes of COVID-19 Infections in Vaccinated Patients with Inflammatory Bowel Disease: Data From an International Registry. Inflamm Bowel Dis 2022; 28:1126.</a></li><li><a class="nounderline abstract_t">Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021; 70:635.</a></li><li><a class="nounderline abstract_t">Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol 2021; 6:218.</a></li><li><a class="nounderline abstract_t">Wong SY, Dixon R, Martinez Pazos V, et al. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021; 161:715.</a></li><li><a class="nounderline abstract_t">Kappelman MD, Weaver KN, Boccieri M, et al. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. Gastroenterology 2021; 161:1340.</a></li><li><a class="nounderline abstract_t">Melmed GY, Botwin GJ, Sobhani K, et al. Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease. Ann Intern Med 2021; 174:1768.</a></li><li><a class="nounderline abstract_t">Frey S, Chowdhury R, Connolly CM, et al. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022; 20:1609.</a></li><li><a class="nounderline abstract_t">Jena A, James D, Singh AK, et al. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2022; 20:1456.</a></li><li><a class="nounderline abstract_t">Caldera F, Knutson KL, Saha S, et al. Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. Am J Gastroenterol 2022; 117:176.</a></li><li><a class="nounderline abstract_t">Caldera F, Farraye FA, Necela BM, et al. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Inflamm Bowel Dis 2023; 29:1202.</a></li><li><a class="nounderline abstract_t">Schell TL, Knutson KL, Saha S, et al. Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022; 28:1781.</a></li><li><a class="nounderline abstract_t">Charilaou P, Tricarico C, Battat R, et al. Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination. Clin Gastroenterol Hepatol 2022; 20:e1493.</a></li><li><a class="nounderline abstract_t">Lin S, Kennedy NA, Saifuddin A, et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022; 13:1379.</a></li><li><a class="nounderline abstract_t">Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology 2022; 162:454.</a></li><li><a class="nounderline abstract_t">Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021; 161:827.</a></li><li><a class="nounderline abstract_t">Windsor JW, Underwood FE, Brenner E, et al. Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. Am J Gastroenterol 2020; 115:1923.</a></li><li><a class="nounderline abstract_t">Ricciuto A, Lamb CA, Benchimol EI, et al. Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2022; 16:591.</a></li><li class="breakAll">SECURE-EoE/EGID Registry. https://eureos.online/newsreader-2102/secure-eoe-egid-registry.html (Accessed on December 08, 2023).</li><li class="breakAll">https://www.asge.org/home/advanced-education-training/covid-19-asge-updates-for-members/gastroenterology-professional-society-guidance-on-endoscopic-procedures-during-the-covid-19-pandemic (Accessed on April 30, 2020).</li><li class="breakAll">https://webfiles.gi.org/links/media/Joint_GI_Society_Guidance_on_Endoscopic_Procedure_During_COVID19_FINAL_impending_3312020.pdf (Accessed on April 30, 2020).</li><li class="breakAll">AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update https://www.sciencedirect.com/science/article/pii/S0016508521030298?via%3Dihub (Accessed on May 24, 2021).</li><li><a class="nounderline abstract_t">Sultan S. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARSCoV2 Testing and Endoscopy. Gastroenterology 2020.</a></li><li class="breakAll">AGA/DHPA joint guidance for resumption of elective endoscopy https://gastro.org/news/aga-dhpa-release-guidance-for-resuming-elective-endoscopy/?hilite=%27covid%27%2C%2719%27 (Accessed on May 25, 2021).</li><li><a class="nounderline abstract_t">Cavaliere K, Levine C, Wander P, et al. Management of upper GI bleeding in patients with COVID-19 pneumonia. Gastrointest Endosc 2020; 92:454.</a></li><li><a class="nounderline abstract_t">Mauro A, De Grazia F, Lenti MV, et al. Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. Clin Res Hepatol Gastroenterol 2021; 45:101521.</a></li><li><a class="nounderline abstract_t">Melazzini F, Lenti MV, Mauro A, et al. Peptic Ulcer Disease as a Common Cause of Bleeding in Patients with Coronavirus Disease 2019. Am J Gastroenterol 2020; 115:1139.</a></li><li><a class="nounderline abstract_t">Sethi A, Swaminath A, Latorre M, et al. Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. Clin Gastroenterol Hepatol 2020; 18:1673.</a></li><li><a class="nounderline abstract_t">Lau JYW, Yu Y, Tang RSY, et al. Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding. N Engl J Med 2020; 382:1299.</a></li><li><a class="nounderline abstract_t">Kim J, Doyle JB, Blackett JW, et al. Effect of the Coronavirus 2019 Pandemic on Outcomes for Patients Admitted With Gastrointestinal Bleeding in New York City. Gastroenterology 2020; 159:1155.</a></li></ol></div><div id="topicVersionRevision">Topic 127965 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (Accessed on May 12, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alamario CV, Chey WD, Spiegel BMR. 2020. AM J Gastro [in press]. https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf (Accessed on July 13, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171057" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Implications of COVID-19 for patients with pre-existing digestive diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247695" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32348641" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283100" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32425234" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553760" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TNFα-Antagonist Use and Mucosal Inflammation Are Associated with Increased Intestinal Expression of SARS-CoV-2 Host Protease TMPRSS2 in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109013" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Characteristics of Coronavirus Disease 2019 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32290077" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996437" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333601" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32314792" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32287140" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32753138" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333911" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251668" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32241899" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446696" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Initial Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 112 Patients From Veracruz in Southeastern Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205220" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213556" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32311512" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diarrhea Is Associated With Prolonged Symptoms and Viral Carriage in Corona Virus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222988" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33009054" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145190" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Liver injury in COVID-19: management and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407808" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970139" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32675498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastrointestinal Complications in Critically Ill Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32311321" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752960" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cyclosporin A inhibits the replication of diverse coronaviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407806" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of COVID-19 Outbreak on the Management of Patients With Severe IBD: A Domino Effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305331" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171076" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272113" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272113" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32303607" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043983" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278362" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082265" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of IBD medications on COVID-19 outcomes: results from an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082265" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of IBD medications on COVID-19 outcomes: results from an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330477" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32619003" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238372" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcomes of COVID-19 Infections in Vaccinated Patients with Inflammatory Bowel Disease: Data From an International Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33472895" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33508241" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33887219" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34144046" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34633830" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34998996" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35189387" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34797219" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36103273" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35396992" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34896283" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35296643" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34717923" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048782" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33156119" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570886" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570886" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570886" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570886" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARSCoV2 Testing and Endoscopy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARSCoV2 Testing and Endoscopy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32325065" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Management of upper GI bleeding in patients with COVID-19 pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888875" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618672" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Peptic Ulcer Disease as a Common Cause of Bleeding in Patients with Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330565" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242355" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405086" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of the Coronavirus 2019 Pandemic on Outcomes for Patients Admitted With Gastrointestinal Bleeding in New York City.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
